We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

88 hedge funds and large institutions have $461M invested in BioCryst Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 13

75% more capital invested

Capital invested by funds: $264M → $461M (+$197M)

43% more call options, than puts

Call options by funds: $10.9M | Put options by funds: $7.64M

24% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 21

17% more funds holding

Funds holding: 75 → 88 (+13)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
88
Holders Change
+13
Holders Change %
+17.33%
% of All Funds
2.54%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
26
Increased
26
Reduced
21
Closed
13
Calls
$10.9M
Puts
$7.64M
Net Calls
+$3.26M
Net Calls Change
+$20K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$68.1M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$16.9M
3
State Street
State Street
Massachusetts
+$16.8M
4
CAM
Cormorant Asset Management
Massachusetts
+$9.6M
5
TAM
THB Asset Management
Connecticut
+$3.21M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$8.88M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$8.23M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$3.96M
4
TC
TFS Capital
Pennsylvania
-$3.8M
5
SGAM
Smith Group Asset Management
Texas
-$2.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$95.1M +$68.1M +6,388,681 +245%
BBA
2
Baker Bros. Advisors
New York
$62.1M -$8.88M -832,948 -12%
RCM
3
RA Capital Management
Massachusetts
$46M – – –
Wellington Management Group
4
Wellington Management Group
Massachusetts
$42.5M -$8.23M -771,469 -16%
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$21.9M -$3.96M -371,117 -15%
Vanguard Group
6
Vanguard Group
Pennsylvania
$18.9M +$439K +41,196 +2%
VM
7
VHCP Management
New York
$18.5M -$107K -10,000 -0.6%
State Street
8
State Street
Massachusetts
$17.3M +$16.8M +1,579,735 +2,692%
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$16.7M +$16.9M +1,583,000 New
CAM
10
Cormorant Asset Management
Massachusetts
$12.4M +$9.6M +900,000 +336%
TGHSA
11
TPG Group Holdings (SBS) Advisors
Texas
$12.3M – – –
BIT
12
BlackRock Institutional Trust
California
$11.4M -$557K -52,256 -5%
DM
13
Deerfield Management
New York
$9.61M +$420K +39,350 +5%
BFA
14
BlackRock Fund Advisors
California
$9.5M +$675K +63,343 +8%
Millennium Management
15
Millennium Management
New York
$6.24M -$576K -54,003 -8%
Connor, Clark & Lunn Investment Management (CC&L)
16
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$6.17M +$2.25M +211,220 +67%
QF
17
QVT Financial
New York
$5.56M – – –
Morgan Stanley
18
Morgan Stanley
New York
$5.56M -$82.2K -7,706 -1%
Jennison Associates
19
Jennison Associates
New York
$3.79M +$12.8K +1,205 +0.3%
TAM
20
THB Asset Management
Connecticut
$3.19M +$3.21M +301,529 New
Geode Capital Management
21
Geode Capital Management
Massachusetts
$2.95M +$608K +57,029 +26%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$2.91M +$2.93M +274,667 New
PAM
23
Panagora Asset Management
Massachusetts
$2.6M +$2.62M +246,190 New
Jane Street
24
Jane Street
New York
$1.91M +$1.92M +180,460 New
U
25
UBS
Switzerland
$1.75M +$863K +80,903 +96%
1
2 3 4 5

BCRX Hedge Fund Activity: Q1 2014 in Review

88 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2014, worth a combined $461M — up 75% from $264M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new BCRX positions and 13 closed out — a net gain of 13 holders — while 26 added to existing stakes and 21 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $68.1M. The largest seller was Baker Bros. Advisors, cutting an estimated $8.88M.

  • 88 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2014, up from 75 in Q4 2013.
  • Funds reported $461M of BioCryst Pharmaceuticals stock for Q1 2014, up 75% quarter-over-quarter.
  • 26 funds opened new BioCryst Pharmaceuticals positions in Q1 2014 and 13 closed out, a net change of +13 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q1 2014 was Fidelity Investments, an estimated $68.1M added.
  • The largest BioCryst Pharmaceuticals seller in Q1 2014 was Baker Bros. Advisors, an estimated $8.88M sold.

Based on aggregated 13F filings for Q1 2014.